Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer
Express Pharma
FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability
The Federation of Pharma Entrepreneurs (FOPE) has urged the National Pharmaceutical Pricing Authority (NPPA) to reconsider a reported proposal to exempt retailers, hospitals, nursing homes and other downstream sellers from […] The post FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability appeared first on Express Pharma.
Read Full Article
Pharma Tech
Pineapples and green tea: FDA turns to public for new approaches to botanical drugs
The FDA is looking to modernise its regulatory framework for drugs derived from plants, algae, and fungi.
Read Full Article
Pharma Tech
Ionis nets Zanvastro US approval in first for Alexander disease
Ionis claims Zanvastro will become available to US patients with rare neurodegenerative condition, Alexander disease “in the coming weeks”.
Read Full Article
Pharma Tech
FDA rallies HRT manufacturers amid US-wide estradiol patch shortage
The uptick in demand for HRT comes shortly after the FDA removed the long-standing black box label warning from such products.
Read Full Article
Pharma Tech
Superluminal Medicines secures $60m to advance rare obesity therapy
Superluminal Medicines has completed a $60m Series B round to support its research into therapies for rare genetic forms of obesity.
Read Full Article
Sponsored content
Featured promotional
News
Latest stories
ET Pharma
Sep 6, 2026, 5:31 AM
Promoter Fosun Pharma sells 4.5% stake in Gland Pharma for â‚ą2,121 crore
Fosun Pharma Industrial Pte Ltd, one of the promoters of Gland Pharma, offloaded 75,05,500 shares in 11 tranches, representing a 4.55 per cent stake in the Hyderabad-based pharma company.
ET Pharma
Sep 6, 2026, 5:30 AM
Seized Abhayrab vials not manufactured by company: Indian Immunologicals Limited
The company said 17 differences were recorded between the seized vials and the retention samples of the same batch held at the CDL
ET Pharma
Sep 6, 2026, 5:25 AM
Novartis India to pursue therapy-aligned acquisitions; eyes expansion in Tier 2 and Tier 3 markets
The company's future strategy focuses on five anchor therapy areas: pain management, wellness, women's health, neuroscience, and transplant immunology. It aims to build new avenues for growth by protecting and extending the equity of brands such as Voveran, Calcium Sandoz, Methergin, Tegrital, Myfortic, and Simulect.
PharmaShots
Sep 4, 2026, 12:30 PM
Samsung Bioepis Reports MHLW Approval of its Ustekinumab Biosimilar
Shots: Ref: Samsung Bioepis |  Image: Samsung Bioepis |   Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Samsung Bioepis Reports MHLW Approval of its Ustekinumab Biosimilar appeared first on PharmaShots.
Express Pharma
Sep 4, 2026, 11:35 AM
FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability
The Federation of Pharma Entrepreneurs (FOPE) has urged the National Pharmaceutical Pricing Authority (NPPA) to reconsider a reported proposal to exempt retailers, hospitals, nursing homes and other downstream sellers from […] The post FOPE opposes proposed exemption of retailers, hospitals from DPCO overcharging liability appeared first on Express Pharma.
PharmaShots
Sep 4, 2026, 11:30 AM
Milestone Pharmaceuticals Reports the NMPA Approval of Etripamil Nasal Spray for PSVT
Shots: Ref: Globenewswire |  Image: Milestone |   Press Release PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com The post Milestone Pharmaceuticals Reports the NMPA Approval of Etripamil Nasal Spray for PSVT appeared first on PharmaShots.
News
Latest industry coverage
Google News
Sep 6, 2026, 5:05 AM
Novartis India Eyes Growth: Acquisitions & Tier 2/3 Expansion - Rediff MoneyWiz
Novartis India Eyes Growth: Acquisitions & Tier 2/3 Expansion  Rediff MoneyWiz
Google News
Sep 6, 2026, 4:36 AM
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data - simplywall.st
Alnylam Pharmaceuticals (ALNY) Could Be 39% Undervalued On Fresh ESC 2026 Data  simplywall.st
Google News
Sep 6, 2026, 4:16 AM
Turkey Strip Pack Aluminum Foil Printed - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
Turkey Strip Pack Aluminum Foil Printed - Market Analysis, Forecast, Size, Trends and Insights  IndexBox
Google News
Sep 6, 2026, 4:05 AM
Big pharma eyes Australian biotech as $300b patent cliff looms - AFR
Big pharma eyes Australian biotech as $300b patent cliff looms  AFR
Google News
Sep 5, 2026, 10:00 PM
Hanmi Pharmaceutical pairs eppe with digital tools to reshape obesity care in Korea - CHOSUNBIZ - Chosunbiz
Hanmi Pharmaceutical pairs eppe with digital tools to reshape obesity care in Korea - CHOSUNBIZÂ Â Chosunbiz
Google News
Sep 5, 2026, 8:14 PM
India’s pharma rise driven by innovation push: Ex-US NIH Director - DD News
India’s pharma rise driven by innovation push: Ex-US NIH Director  DD News
Google News
Sep 5, 2026, 7:41 PM
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines - BioPharma Dive
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines  BioPharma Dive
Google News
Sep 5, 2026, 7:40 PM
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Aspire Trial Failure And Expense Cut Plans - simplywall.st
Why Ultragenyx Pharmaceutical (RARE) Is Down 40.3% After Aspire Trial Failure And Expense Cut Plans  simplywall.st
Google News
Sep 5, 2026, 7:32 PM
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does. - The Motley Fool
Will Eli Lilly Split Its Stock? Here's What History Says Will Happen If It Does.  The Motley Fool
Sponsored placement
Featured promotions
Sponsored
Jeplus.in
Purchase All Medicines.Get 10% Offer